DrugPatentWatch Database Preview
Drugs in Development Information for Darapladib
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Darapladib?
Darapladib is an investigational drug.
There have been 19 clinical trials for Darapladib.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2010.
The most common disease conditions in clinical trials are Atherosclerosis, Coronary Artery Disease, and Myocardial Ischemia. The leading clinical trial sponsors are GlaxoSmithKline, National Heart, Lung, and Blood Institute (NHLBI), and The TIMI Study Group.
Summary for Darapladib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 94 |
| WIPO Patent Applications | 83 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2010-02-01) |
| Vendors | 56 |
Recent Clinical Trials for Darapladib
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM) | GlaxoSmithKline | Phase 1 |
| Darapladib China PK | GlaxoSmithKline | Phase 1 |
| Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects | GlaxoSmithKline | Phase 1 |
Clinical Trial Summary for Darapladib
Top disease conditions for Darapladib
Top clinical trial sponsors for Darapladib
US Patents for Darapladib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
